发明名称 |
CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES |
摘要 |
<p>In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-α-2b stimulatory cytokines.</p> |
申请公布号 |
EP1996232(A4) |
申请公布日期 |
2010.08.04 |
申请号 |
EP20070751592 |
申请日期 |
2007.02.23 |
申请人 |
JANSSEN PHARMACEUTICA N.V. |
发明人 |
CAI, ZELING;MORIARTY, ANN;PETERSON, PER, A.;RICHARDS, JON, M. |
分类号 |
A61K45/00;A01N63/00;A61K38/21 |
主分类号 |
A61K45/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|